Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis

INTRODUCTION: Biomarkers complementing clinical evaluations may help to reduce the length and size of proof-of-concept (PoC) trials aimed to obtain quick “go/no go” decisions in the clinical development of new treatments. We aimed to identify and validate serum biomarkers with a high sensitivity to...

Descripción completa

Detalles Bibliográficos
Autores principales: Turina, Maureen C, Yeremenko, Nataliya, Paramarta, Jacqueline E, De Rycke, Leen, Baeten, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293104/
https://www.ncbi.nlm.nih.gov/pubmed/25135077
http://dx.doi.org/10.1186/s13075-014-0413-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293104/
https://www.ncbi.nlm.nih.gov/pubmed/25135077
http://dx.doi.org/10.1186/s13075-014-0413-4

Ejemplares similares